Back to Search
PETER RICHARDSON, MD
MD
Specialist
NPI: 1194720102Individual
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
0101032138(VA)
Research & Publications (20)
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
PMID 19471019·Blood·2009
3-trial
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
PMID 19528374·J Clin Oncol·2009
8-other
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
PMID 19170677·Br J Haematol·2009
3-trial
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.
PMID 18297527·Leuk Lymphoma·2008
3-trial
Bortezomib in the front-line treatment of multiple myeloma.
PMID 18588451·Expert Rev Anticancer Ther·2008
6-review
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
PMID 17690257·Blood·2007
3-trial
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
PMID 17451408·Br J Haematol·2007
2-rct
The treatment of relapsed and refractory multiple myeloma.
PMID 18024646·Hematology Am Soc Hematol Educ Program·2007
6-review
The emerging role of novel therapies for the treatment of relapsed myeloma.
PMID 17335684·J Natl Compr Canc Netw·2007
6-review
Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
PMID 16832859·Clin Adv Hematol Oncol·2006
8-other
Can thalidomide improve outcome in patients with multiple myeloma?
PMID 17080171·Nat Clin Pract Oncol·2006
8-other
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
PMID 16830422·Clin Adv Hematol Oncol·2006
8-other
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
PMID 16840727·Blood·2006
3-trial
Bortezomib: proteasome inhibition as an effective anticancer therapy.
PMID 16409135·Annu Rev Med·2006
6-review
Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation.
PMID 16773847·Oncology (Williston Park)·2006
5-case
Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
PMID 16988581·Curr Opin Oncol·2006
6-review
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
PMID 16754936·J Clin Oncol·2006
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1500 COMMERCE RD
STAUNTON, VA 24401 - Phone
- (540) 213-0060
Quick Facts
- NPI
- 1194720102
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile